“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.

Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...

Takeda Canada Inc. (“Takeda”) is pleased to announce that Ontario Drug Benefit (ODB) include FruzaqlaTM (fruquintinib capsules) in the list of drugs eligible for ...

But is the combination a "viable alternative" to nivolumab and ipilimumab?

Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.

Stage 4 colon cancer symptoms like pain and bowel changes can be managed with medicine. Stage 4 colon cancer is not curable, but treatment can help people live longer. Removing a few metastases in the ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Oct. 22, 2002 — For treatment of metastatic colon cancer, adding oxaliplatin to 5-fluorouracil (5-FU) and leucovorin continues to be superior to 5-FU and leucovorin alone in terms of response rates ...